Industry Insider News

Organogenesis Announces New ‘Q’ Code for PuraPly

Beginning Jan. 1, PuraPly™ Antimicrobial Wound Matrix by Organogenesis Inc., Canton, MA, has a new Healthcare Common Procedure Coding System code: Q4172. Wound care providers can now:

• use the new “Q” code for all sites of care and
• replace the C9349 code with the new code.

PuraPly is now the only skin substitute with pass-through reimbursement for hospital outpatient and ambulatory surgery centers settings through 2017, according to company officials.

Nation Divided Over Price’s Appointment to HHS?

Although the American Medical Association has endorsed the selection of one of its own physicians, orthopedic surgeon Tom Price, MD, (R-Georgia) to serve as secretary of the U.S. Department of Health & Human Services (HHS), there appears to be split feeling among the country’s doctors and nurses in general.

According to a report by the New York Times, more than 5,000 doctors have signed a petition claim that Price, known for his advocacy of those in the healthcare industry and his criticism of Obamacare, “does not speak for us.”

To read the full report, click here: www.nytimes.com/2016/12/26/us/tom-price-hhs-donald-trump-cabinet.html?emc=edit_th_20161227&nl=todaysheadlines&nlid=65963610

Tricol Biomedical Inc. Announces New Website & Corporate Rebrand

Tricol Biomedical Inc., Portland, OR, a wholly owned subsidiary of Tricol International Group, Ltd, and a developer/marketer of HemCon^® advanced wound care products, has launched a new website: www.tricolbiomedical.com.

The new site now has richer online content and provides an enhanced user experience, company officials said. The improved site makes it easy to navigate through content and share information with others across all social media applications and offers a responsive layout on all platforms, including mobile devices.

The site design also allows for streamlined menus and clear navigation that feature relevant content and product information to help better educate customers on the HemCon line of products and solutions. The site is also designed to facilitate access to technical data, an education center, distribution options, and enhance customer interactions.

"Since the acquisition of HemCon Medical Technologies Inc. in April 2016 and the subsequent rebrand to Tricol Biomedical Inc., the company has been able to fine-tune and focus its strategic direction to expand as a key player in the medical-device industry," said Michael Wax, chief executive officer of Tricol Biomedical.

Arteriocyte Inc. Changes Name To Compass Biomedical

Arteriocyte Inc., the research and development division of the Arteriocyte^TM family of companies, has announced it’s new business name — Compass Biomedical. The name change and reorganization follow the recent acquisition of the orthopedic-focused division Arteriocyte Medical Systems Inc., including the Arteriocyte trademark by ISTO Technologies.

The reorganization allows Compass Biomedical to focus on developing platelet-derived products for cell culture, wound care, and ophthalmic applications and expand its core research and manufacturing capabilities as a new contract service provider to organizations in the space, officials said.

Compass Biomedical was founded in 2004 when a hematologist and a cardiologist teamed up to use a patient's own bone marrow-derived stem cells as treatment following a heart attack. Cellular therapy is the foundation of Compass Biomedical and continues to be the company's focus with their BioBandage,™ PLUS,™ and NANEX™ products.

"The new name, Compass Biomedical, allows us to emphasize our commitment to our customers," said Compass Biomedical chief executive officer Don Brown. "Just as a compass is a tool that explorers use to find direction, we want our customers to trust that they can depend on Compass to guide them through the transition from research to the clinic by providing them with the best quality products and services."